Methylprednisolone iv (DrugBank: Methylprednisolone)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
13 | Multiple sclerosis/Neuromyelitis optica | 2 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02545959 (ClinicalTrials.gov) | November 30, 2015 | 7/9/2015 | Intrathecal Rituximab in Progressive Multiple Sclerosis | Intrathecal Rituximab in Progressive Multiple Sclerosis | Multiple Sclerosis, Chronic Progressive;Nervous System Diseases | Drug: Rituximab IT;Drug: methylprednisolone IV;Drug: Rituximab IV | Centre Hospitalier de PAU | University Hospital, Bordeaux | Completed | 45 Years | N/A | All | 10 | Phase 2 | France |
2 | NCT00984984 (ClinicalTrials.gov) | March 2008 | 24/9/2009 | Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis (MS) Relapses | Randomised Double-blinded Trial Comparing Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis Relapses | Multiple Sclerosis, Relapsing-Remitting | Drug: methylprednisolone PO;Drug: methylprednisolone IV | Rennes University Hospital | NULL | Recruiting | 18 Years | 55 Years | Both | 200 | Phase 3 | France |